Literature DB >> 3108008

Ketanserin and the arterial baroreceptor reflex in normotensive subjects.

A Berdeaux, A Edouard, K Samii, J F Giudicelli.   

Abstract

The effects of oral ketanserin 40 and 120 mg on the responses to baroreflex activation and deactivation by phenylephrine and nitroglycerin, respectively, were investigated in normotensive subjects. Plasma catecholamine levels were measured at the same times. Two hours after the administration of ketanserin, and regardless of its effect on arterial pressure (no change after 40 mg, decrease after 120 mg), there was no alteration either in resting heart rate or baroreflex sensitivity during baroreceptor activation or deactivation. The lack of reflex tachycardia in response to the drug-induced hypotension may be related to the alpha 1-adrenoceptor blockade-mediated sympathoinhibitory effect of ketanserin, which leaves unaffected both plasma catecholamines and the normal reactivity of the sympathetic system.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3108008     DOI: 10.1007/bf00609954

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  Diminished baroreflex sensitivity in high blood pressure.

Authors:  J D Bristow; A J Honour; G W Pickering; P Sleight; H S Smyth
Journal:  Circulation       Date:  1969-01       Impact factor: 29.690

2.  Mechanism of antihypertensive action of ketanserin in man.

Authors:  I W Reimann; J C Frölich
Journal:  Br Med J (Clin Res Ed)       Date:  1983-08-06

3.  Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man.

Authors:  D Trenk; A Mosler; W Kirch; T Meinertz; E Jähnchen
Journal:  J Cardiovasc Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.105

4.  High-performance liquid chromatographic assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine.

Authors:  P O Okonkwo; I W Reimann; R Woestenborghs; U Klotz
Journal:  J Chromatogr       Date:  1983-02-11

5.  Experience with ketanserin, a serotonin (S2) antagonist, in longterm treatment of essential hypertension.

Authors:  T Hedner; B Persson; G Berglund
Journal:  Clin Exp Hypertens A       Date:  1984

6.  Attenuation by diltiazem of arterial baroreflex sensitivity in man.

Authors:  J F Giudicelli; A Berdeaux; A Edouard; F Lhoste; C Richer; C Thuillez; A Jacolot
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  The effects of ketanserin, methysergide and LY 53857 on sympathetic nerve activity.

Authors:  A G Ramage
Journal:  Eur J Pharmacol       Date:  1985-07-31       Impact factor: 4.432

8.  Ketanserin and alpha 1-adrenergic antagonism in humans.

Authors:  J R Zabludowski; S G Ball; J I Robertson
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

9.  Evidence for a central sympathoinhibitory action of prazosin and indoramin.

Authors:  A G Ramage
Journal:  Eur J Pharmacol       Date:  1986-02-11       Impact factor: 4.432

10.  The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects.

Authors:  J F Giudicelli; A Berdeaux; A Edouard; C Richer; D Jacolot
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

View more
  2 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Interference of ketanserin with baroreflex control of the circulation in the conscious spontaneously hypertensive rat.

Authors:  J Smits; F van Dorsten; H Struyker Boudier
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.